Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis

Autor: Shank, B.R., Primeaux, B., Yeung, E.K., Horowitz, S.B., Lee, I.Y., Roccograndi, L., Feng, L., Kaufman, G.P., Lee, H.C., Manasanch, E.E., Patel, K.K., Orlowski, R.Z., Weber, D.M., Becnel, M.R., Thomas, S.K.
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia April 2023 23(4):279-290
Databáze: ScienceDirect
Externí odkaz: